InBody Co.,Ltd Logo

InBody Co.,Ltd

041830.KQ

(0.0)
Stock Price

21.700,00 KRW

12.28% ROA

14.47% ROE

8.67x PER

Market Cap.

315.901.476.250,00 KRW

1.08% DER

1.24% Yield

19.65% NPM

InBody Co.,Ltd Stock Analysis

InBody Co.,Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

InBody Co.,Ltd Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

InBody Co.,Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

InBody Co.,Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

InBody Co.,Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

InBody Co.,Ltd Revenue
Year Revenue Growth
2012 33.230.296.360
2013 36.786.609.020 9.67%
2014 48.940.140.490 24.83%
2015 68.949.097.530 29.02%
2016 79.848.382.290 13.65%
2017 93.253.712.994 14.38%
2018 99.635.442.563 6.41%
2019 117.058.914.069 14.88%
2020 107.122.053.678 -9.28%
2021 137.836.961.994 22.28%
2022 160.003.774.093 13.85%
2023 162.641.406.400 1.62%
2023 170.351.229.733 4.53%
2024 200.972.323.528 15.24%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

InBody Co.,Ltd Research and Development Expenses
Year Research and Development Expenses Growth
2012 2.289.212.000
2013 2.710.807.000 15.55%
2014 3.392.417.000 20.09%
2015 4.882.220.000 30.51%
2016 5.376.619.000 9.2%
2017 7.250.497.000 25.84%
2018 5.210.831.000 -39.14%
2019 5.242.765.000 0.61%
2020 5.800.563.000 9.62%
2021 8.061.689.000 28.05%
2022 8.778.754.000 8.17%
2023 8.419.760.000 -4.26%
2023 9.312.135.908 9.58%
2024 13.489.520.000 30.97%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

InBody Co.,Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 306.033.000
2013 238.505.000 -28.31%
2014 381.384.000 37.46%
2015 388.854.000 1.92%
2016 507.228.000 23.34%
2017 580.536.000 12.63%
2018 557.027.000 -4.22%
2019 562.904.000 1.04%
2020 3.949.218.000 85.75%
2021 3.714.035.000 -6.33%
2022 4.492.131.000 17.32%
2023 794.856.000 -465.15%
2023 5.960.065.000 86.66%
2024 118.908.576.000 94.99%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

InBody Co.,Ltd EBITDA
Year EBITDA Growth
2012 5.575.729.970
2013 7.401.870.390 24.67%
2014 11.203.785.610 33.93%
2015 21.376.543.260 47.59%
2016 23.788.949.780 10.14%
2017 26.510.988.300 10.27%
2018 25.692.526.680 -3.19%
2019 31.554.646.950 18.58%
2020 23.429.238.170 -34.68%
2021 40.287.424.990 41.84%
2022 46.078.054.760 12.57%
2023 40.528.693.760 -13.69%
2023 44.257.594.710 8.43%
2024 43.114.528.920 -2.65%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

InBody Co.,Ltd Gross Profit
Year Gross Profit Growth
2012 23.605.964.200
2013 25.874.038.640 8.77%
2014 34.166.444.060 24.27%
2015 48.547.847.124 29.62%
2016 56.806.083.631 14.54%
2017 68.407.860.342 16.96%
2018 71.782.517.512 4.7%
2019 83.116.041.076 13.64%
2020 73.881.778.608 -12.5%
2021 97.883.757.767 24.52%
2022 117.129.466.706 16.43%
2023 125.164.187.360 6.42%
2023 128.114.054.480 2.3%
2024 150.829.173.308 15.06%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

InBody Co.,Ltd Net Profit
Year Net Profit Growth
2012 5.642.751.340
2013 6.194.379.890 8.91%
2014 8.879.319.650 30.24%
2015 17.310.909.053 48.71%
2016 16.986.909.670 -1.91%
2017 19.321.817.541 12.08%
2018 19.670.670.946 1.77%
2019 20.428.475.389 3.71%
2020 17.517.981.150 -16.61%
2021 34.033.492.960 48.53%
2022 33.815.534.170 -0.64%
2023 28.181.457.280 -19.99%
2023 36.722.823.520 23.26%
2024 33.205.160.000 -10.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

InBody Co.,Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 415
2013 455 8.79%
2014 652 30.21%
2015 1.272 48.7%
2016 1.248 -1.92%
2017 1.430 12.8%
2018 1.459 1.92%
2019 1.532 4.77%
2020 1.335 -14.68%
2021 2.613 48.89%
2022 2.596 -0.66%
2023 2.163 -19.97%
2023 2.819 23.27%
2024 2.549 -10.64%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

InBody Co.,Ltd Free Cashflow
Year Free Cashflow Growth
2012 3.543.282.430
2013 3.657.640.440 3.13%
2014 8.792.349.700 58.4%
2015 3.628.898.553 -142.29%
2016 9.832.908.339 63.09%
2017 12.994.888.527 24.33%
2018 -23.233.824.849 155.93%
2019 20.936.579.533 210.97%
2020 26.580.853.131 21.23%
2021 18.513.997.035 -43.57%
2022 24.402.030.931 24.13%
2023 9.337.038.950 -161.35%
2023 31.043.757.215 69.92%
2024 4.503.749.374 -589.29%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

InBody Co.,Ltd Operating Cashflow
Year Operating Cashflow Growth
2012 4.355.328.120
2013 6.994.673.360 37.73%
2014 10.259.230.790 31.82%
2015 11.178.514.967 8.22%
2016 18.238.319.925 38.71%
2017 18.576.147.005 1.82%
2018 17.704.892.096 -4.92%
2019 24.206.000.619 26.86%
2020 28.500.349.902 15.07%
2021 30.350.938.961 6.1%
2022 30.418.862.594 0.22%
2023 11.073.886.430 -174.69%
2023 38.686.124.129 71.38%
2024 6.412.676.227 -503.28%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

InBody Co.,Ltd Capital Expenditure
Year Capital Expenditure Growth
2012 812.045.690
2013 3.337.032.920 75.67%
2014 1.466.881.090 -127.49%
2015 7.549.616.414 80.57%
2016 8.405.411.586 10.18%
2017 5.581.258.478 -50.6%
2018 40.938.716.945 86.37%
2019 3.269.421.086 -1152.17%
2020 1.919.496.771 -70.33%
2021 11.836.941.926 83.78%
2022 6.016.831.663 -96.73%
2023 1.736.847.480 -246.42%
2023 7.642.366.914 77.27%
2024 1.908.926.853 -300.35%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

InBody Co.,Ltd Equity
Year Equity Growth
2012 46.134.394.300
2013 51.558.488.020 10.52%
2014 59.610.449.950 13.51%
2015 76.349.656.832 21.92%
2016 92.332.630.557 17.31%
2017 106.516.223.452 13.32%
2018 124.532.453.304 14.47%
2019 139.830.175.109 10.94%
2020 150.182.330.495 6.89%
2021 183.782.288.340 18.28%
2022 216.039.393.702 14.93%
2023 249.834.875.848 13.53%
2023 230.506.659.540 -8.39%
2024 263.796.103.471 12.62%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

InBody Co.,Ltd Assets
Year Assets Growth
2012 48.162.809.780
2013 53.672.981.910 10.27%
2014 63.171.082.010 15.04%
2015 82.459.250.482 23.39%
2016 97.059.397.401 15.04%
2017 112.024.745.207 13.36%
2018 131.686.125.520 14.93%
2019 154.903.555.776 14.99%
2020 166.150.336.180 6.77%
2021 203.760.043.204 18.46%
2022 242.665.327.372 16.03%
2023 274.456.137.995 11.58%
2023 258.836.010.290 -6.03%
2024 296.853.298.043 12.81%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

InBody Co.,Ltd Liabilities
Year Liabilities Growth
2012 2.028.415.480
2013 1.918.484.690 -5.73%
2014 3.394.163.510 43.48%
2015 6.109.593.650 44.45%
2016 4.726.766.844 -29.26%
2017 5.508.521.755 14.19%
2018 7.153.672.216 23%
2019 15.073.380.667 52.54%
2020 15.968.005.685 5.6%
2021 19.977.754.864 20.07%
2022 26.625.933.670 24.97%
2023 24.621.262.147 -8.14%
2023 28.329.350.750 13.09%
2024 33.057.194.572 14.3%

InBody Co.,Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
14227.26
Net Income per Share
2796.36
Price to Earning Ratio
8.67x
Price To Sales Ratio
1.7x
POCF Ratio
9.9
PFCF Ratio
13.27
Price to Book Ratio
1.2
EV to Sales
1.61
EV Over EBITDA
6.66
EV to Operating CashFlow
9.37
EV to FreeCashFlow
12.56
Earnings Yield
0.12
FreeCashFlow Yield
0.08
Market Cap
315,90 Bil.
Enterprise Value
298,93 Bil.
Graham Number
35612.81
Graham NetNet
8176.58

Income Statement Metrics

Net Income per Share
2796.36
Income Quality
0.88
ROE
0.14
Return On Assets
0.12
Return On Capital Employed
0.14
Net Income per EBT
0.83
EBT Per Ebit
1.15
Ebit per Revenue
0.21
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0.32
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.75
Operating Profit Margin
0.21
Pretax Profit Margin
0.24
Net Profit Margin
0.2

Dividends

Dividend Yield
0.01
Dividend Yield %
1.24
Payout Ratio
0.13
Dividend Per Share
300

Operating Metrics

Operating Cashflow per Share
2449.16
Free CashFlow per Share
1827.28
Capex to Operating CashFlow
0.25
Capex to Revenue
0.04
Capex to Depreciation
1.22
Return on Invested Capital
0.11
Return on Tangible Assets
0.12
Days Sales Outstanding
48.97
Days Payables Outstanding
22.78
Days of Inventory on Hand
274.64
Receivables Turnover
7.45
Payables Turnover
16.03
Inventory Turnover
1.33
Capex per Share
621.88

Balance Sheet

Cash per Share
7.954,03
Book Value per Share
20.250,19
Tangible Book Value per Share
20236.6
Shareholders Equity per Share
20157.5
Interest Debt per Share
239.17
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
-0.38
Current Ratio
6.54
Tangible Asset Value
263,62 Bil.
Net Current Asset Value
133,87 Bil.
Invested Capital
230625568146
Working Capital
141,38 Bil.
Intangibles to Total Assets
0
Average Receivables
28,51 Bil.
Average Payables
7,16 Bil.
Average Inventory
32567323641
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

InBody Co.,Ltd Dividends
Year Dividends Growth
2001 28
2002 55 50.91%
2003 50 -12.24%
2004 28 -81.48%
2007 100 73%
2008 160 37.5%
2009 160 0%
2010 40 -300%
2011 40 0%
2012 40 0%
2013 40 0%
2014 60 33.33%
2015 80 25%
2016 100 20%
2022 300 66.67%
2023 300 0%

InBody Co.,Ltd Profile

About InBody Co.,Ltd

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.

CEO
Dr. Ki-Chul Cha
Employee
266
Address
InBody Building
Seoul, 06106

InBody Co.,Ltd Executives & BODs

InBody Co.,Ltd Executives & BODs
# Name Age
1 Dr. Ki-Chul Cha
Chief Executive Officer
70
2 Yoon-Sun Shin
Managing Director
70
3 Ju-Sik Shin
Executive Officer
70

InBody Co.,Ltd Competitors

Vieworks Co., Ltd. Logo
Vieworks Co., Ltd.

100120.KQ

(0.0)
Osstem Implant Co., Ltd. Logo
Osstem Implant Co., Ltd.

048260.KQ

(0.0)
Seegene, Inc. Logo
Seegene, Inc.

096530.KQ

(0.0)
Medy-Tox Inc. Logo
Medy-Tox Inc.

086900.KQ

(0.0)